Evans G D, Grimwade D J
Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Leuk Lymphoma. 1999 Apr;33(3-4):219-29. doi: 10.3109/10428199909058422.
All-trans retinoic acid (ATRA) is currently recommended as standard treatment for acute promyelocytic leukemia (APL). However there has been increasing concern that ATRA is associated with unusual sites of relapse. Although there is insufficient evidence so far to substantiate this, we review the potential mechanisms by which ATRA may increase the incidence of extramedullary and, in particular, central nervous system (CNS) relapse.
全反式维甲酸（ATRA）目前被推荐作为急性早幼粒细胞白血病（APL）的标准治疗方法。然而，人们越来越担心ATRA与不寻常的复发部位有关。尽管目前尚无足够证据证实这一点，但我们回顾了ATRA可能增加髓外尤其是中枢神经系统（CNS）复发发生率的潜在机制。
